Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Benjamin O. Anderson MD, FACS Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

Guru P. Sonpavde MD Advisory Board

See All Experts

featured

Published in Oncology

Journal Scan / Research · July 06, 2023

First-Line Systemic Treatment Strategies in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

The Lancet Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Oncology

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Lancet Oncol 2023 Jun 14;[EPub Ahead of Print], MJG Bond, K Bolhuis, OJL Loosveld, JWB de Groot, H Droogendijk, HH Helgason, MP Hendriks, JM Klaase, G Kazemier, MSL Liem, AM Rijken, C Verhoef, JHW de Wilt, KP de Jong, MF Gerhards, MJ van Amerongen, MRW Engelbrecht, KP van Lienden, IQ Molenaar, B de Valk, BCM Haberkorn, ED Kerver, F Erdkamp, RJ van Alphen, D Mathijssen-van Stein, A Komurcu, M Lopez-Yurda, RJ Swijnenburg, CJA Punt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

First-Line Systemic Treatment Strategies in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

Additional Info

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Further Reading

Final Note From the Oncology Editors

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

Recently Updated